We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've ...

It's important that we prioritise those areas of guidance development and delivery that will have greatest impact on the health and care system. One of our core strategic ambitions is to focus on what ...

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

The National Institute for Health and Care Excellence (NICE) is producing late-stage assessment guidance on Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment.

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. This ...